denkapparat Operations GmbH Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

denkapparat Operations GmbH acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 992 shares of the pharmaceutical company’s stock, valued at approximately $399,000.

Several other large investors have also made changes to their positions in VRTX. Larson Financial Group LLC boosted its position in shares of Vertex Pharmaceuticals by 21.9% in the third quarter. Larson Financial Group LLC now owns 417 shares of the pharmaceutical company’s stock valued at $194,000 after acquiring an additional 75 shares during the period. Truvestments Capital LLC acquired a new stake in Vertex Pharmaceuticals during the third quarter worth about $35,000. Qsemble Capital Management LP increased its stake in Vertex Pharmaceuticals by 68.3% during the third quarter. Qsemble Capital Management LP now owns 1,264 shares of the pharmaceutical company’s stock valued at $588,000 after acquiring an additional 513 shares during the period. D.A. Davidson & CO. raised its holdings in Vertex Pharmaceuticals by 12.6% in the 3rd quarter. D.A. Davidson & CO. now owns 5,475 shares of the pharmaceutical company’s stock valued at $2,546,000 after acquiring an additional 611 shares in the last quarter. Finally, Townsquare Capital LLC lifted its position in shares of Vertex Pharmaceuticals by 31.6% in the 3rd quarter. Townsquare Capital LLC now owns 15,054 shares of the pharmaceutical company’s stock worth $7,001,000 after acquiring an additional 3,616 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Ourania Tatsis sold 244 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the completion of the sale, the executive vice president now directly owns 67,695 shares in the company, valued at $30,805,286.70. This trade represents a 0.36 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the transaction, the executive vice president now owns 26,512 shares of the company’s stock, valued at $13,256,000. This trade represents a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock valued at $2,121,012 in the last ninety days. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $502.55 on Friday. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a market cap of $129.05 billion, a P/E ratio of -228.43, a P/E/G ratio of 2.11 and a beta of 0.41. The firm’s fifty day moving average price is $475.04 and its two-hundred day moving average price is $463.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on VRTX shares. HC Wainwright restated a “buy” rating and issued a $550.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Oppenheimer cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Wells Fargo & Company lowered shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price target for the company. in a research report on Thursday, January 30th. StockNews.com upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, March 11th. Finally, Bank of America dropped their target price on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a report on Thursday, December 19th. Ten analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $506.70.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.